Last Update: Jun 08, 2026 

 Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets 

ClinicalTrials.gov Identifier: [NCT07594587](https://clinicaltrials.gov/ct2/show/NCT07594587)

 

Novartis Reference Number:CINC424C1401

 

 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") 

 All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

 

##  Study Description 

This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.



 

 Condition Graft-Versus-Host Disease 

 

 Overall Status Recruiting 

 

 Number of Participants395

 

 

 Start Date May 11, 2026 

 

 Completion Date May 15, 2030 

 

 Gender All 

 

 Age(s) 0 Years - (Child, Adult, Older Adult) 

 

 

 

##  Eligibility Criteria 

Inclusion Criteria:

\* Patients with acute and chronic GVHD  
\* Patients treated with ruxolitinib

Exclusion Criteria:

None

Other protocol-defined inclusion/exclusion criteria may apply.



 

 Japan 

####  Novartis 

Recruiting

 Tokyo,105-6333,Japan

 

 

 

 

 

 

 

 

 

##  Worldwide Contacts 

If the location of your choosing does not feature any contact detail, please reach out using the information below.

#### Novartis Pharmaceuticals

Phone: [ +41613241111](tel:+41613241111) 

Email: <novartis.email@novartis.com>